Complete the form below to download our academic posters.
Poster Presentation
Preliminary safety, tolerability, pharmacokinetic and pharmacodynamic analysis from the ongoing RAISIC-1 (relief of acidic immune suppression in cancer): Phase 1/2 clinical trial of the GPR65 inhibitor of PTT-4256
Download PosterPoster Presentation
A Modular, Open-label, Dose-finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256 (RAISIC-1).
Download PosterPoster Presentation
GPR65 inhibition counteracts low pH-dependant immunosuppressive effects on immune cells and displays pronounced anti-tumor activity in mice: Identification of PTT-4256 as a clinical drug candidate.
Download PosterPoster Presentation
PTT-4256 is a first-in-class GPR65 inhibitor that reverses the immuno-suppressive effects of acidic pH in macrophages, activates anti-tumorigenic pathways in the tumor microenvironment and displays single agent anti-tumor efficacy in mice.
Download PosterSpeaker Presentation
Inhibition of GPR65 counteracts low pH-induced immuno-suppressive polarization of macrophages. In vitro and in vivo characterization of potent, selective and orally bioavailable small molecule GPR65 antagonists.
Download PosterPoster Presentation
Inhibition of acid sensing by GPR65 normalizes gene expression in macrophages, increases immune cell infiltration in tumors, and restrains subcutaneous MC38 growth in mice.
Download PosterPoster Presentation
GPR65 is a critical mediator of low pH-induced immunosuppressive signalling in tumor associated macrophages: human target validation of a novel innate immune checkpoint and small molecule inhibitor drug discovery.
Download Poster
